Familial aggregation of left main coronary artery disease and future risk of coronary events in asymptomatic siblings of affected patients: reply
We thank Dr Patel et al. for their kind interest in our manuscript. Indeed, we agree with the authors that manifestation of atherosclerosis is anatomically diffuse and as such modulated by several, including heritable, risk factors. Also, their notion that left main disease (LMD) is rarely an isolated phenomenon but rather occurs in addition to disease manifestation at other branches of the coronary tree is concordant with our results. Based on their clinical observations, Dr Patel et al. argue that the heritability of LMD is a surrogate of heritability of severe coronary artery disease (CAD) rather than a result from distinct heritable predisposition. They further conclude that coincidence of LMD and severe CAD may explain our finding that relatives of LMD patients have a higher risk of developing incident cardiovascular events, as they might have inherited a more severe underlying atherosclerotic process. 1 In fact, we considered such line of thoughts in our initial analysis. 2 However, in contrast to LMD, we did not find significant heritability estimates for the existence of 1-, 2-, or 3-vessel CAD. 2 Moreover, surrogate phenotypes of CAD severity, like the number of stenoses or the Gensini index seemed not to be markedly influenced by genetic factors. 2 Interestingly, similar observations come from analyses of other traditional risk factors, as it is generally well perceived that they may affect one or the other vascular bed with specific preference.
1 Also, we believe that the mechanism proposed by Dr Patel et al. falls short explaining the higher event rates in relatives of LMD. Indeed, the group used for comparison consisted of individuals who had at least two siblings with evidence of CAD including one with myocardial infarction-but no family history of LMD. 1 (1) AAD is the most critical cardiovascular emergency with a mortality risk of 1% for each hour of evolution. Even though D-Dimer testing may be carried out rapidly, it should not delay the imaging diagnostic work-up. The latter is the only procedure that will conduct the patient promptly to the operating room when appropriate, thus saving his life. Consequently, we believe that D-Dimer test should not be considered as a first line and exclusive screening tool in order to rule out the disease, as it is in suspected deep vein thrombosis. (2) The 0.1 mg/mL threshold proposed is very low and is chosen to obtain the highest sensitivity (100%). However, the authors should also take into account the specificity. On the basis on the ROC curve provided (Figure 2) , one can estimate that for a sensitivity of 100% (Y-axis, upper-right of the curve) the corresponding specificity is at best between 10 and 15%. Even though the sensitivity is high, what is the relevance of a 10 -15% specificity in terms of medical management of AAD? For 100 patients screened with D-Dimer for suspected AAD, only 10 to 15 will be negative. However, 85 to 90 cases the D-Dimer test will be positive thus necessitating a complementary imaging modality. Yet, these explorations will have been delayed as a consequence of the time needed to obtain the D-Dimer test results. In addition, such a low threshold is not applicable to the majority of D-Dimer tests available on the market since the usual cut-off ranges from 0.3 to 0.5 mg/mL (see Table 3 of the paper 1 ). For example, in our own series, setting a threshold at 0.1 mg/mL would be impossible since the detection limit of the test was 0.2 mg/mL. (3) Finally, we wish to point out that even by using an usual cut-off (0.3 -0.5 mg/mL), D-Dimer test could be negative in acute aortic syndrome due to AAD, especially in patients without a patent false lumen presenting with an aortic intramural haematoma.
